BioPharma Dive February 20, 2025
The Trump administration’s move to reduce the FDA’s workforce could imperil important work on devices and food safety, as well as risk the agency’s ability to grow its expertise in new fields.
The firing of possibly thousands of people working in U.S. health agencies this past week is likely to ripple across the biomedical ecosystem, affecting basic scientific research and disease tracking to regulatory oversight of new products.
Enacted by the Trump administration, the layoffs affected a wide range of agencies under the Department of Health and Human Services. The exact number of affected employees at each HHS agency isn’t clear, and a department spokesperson declined to provide details. Reports have indicated up to 5,000 staff across HHS may be...
Today's Sponsors
Today's Sponsor